1. Home
  2. LODE vs CGEN Comparison

LODE vs CGEN Comparison

Compare LODE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comstock Inc.

LODE

Comstock Inc.

HOLD

Current Price

$3.62

Market Cap

167.1M

Sector

Industrials

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.65

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LODE
CGEN
Founded
2008
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
143.1M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LODE
CGEN
Price
$3.62
$1.65
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$4.00
$4.00
AVG Volume (30 Days)
1.2M
458.5K
Earning Date
10-30-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,778,445.00
$6,903,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,798.62
$231.15
P/E Ratio
N/A
N/A
Revenue Growth
48.99
N/A
52 Week Low
$1.67
$1.13
52 Week High
$6.13
$2.66

Technical Indicators

Market Signals
Indicator
LODE
CGEN
Relative Strength Index (RSI) 48.55 55.37
Support Level $3.81 $1.43
Resistance Level $4.10 $1.73
Average True Range (ATR) 0.28 0.07
MACD -0.02 0.02
Stochastic Oscillator 25.19 67.83

Price Performance

Historical Comparison
LODE
CGEN

About LODE Comstock Inc.

Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: